428 related articles for article (PubMed ID: 28317397)
21. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.
Xing T; Xu H; Cao L; Ye M
PLoS One; 2017; 12(1):e0169444. PubMed ID: 28107377
[TBL] [Abstract][Full Text] [Related]
22. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
23. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
24. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?].
Fuentes Olmo J; Uribarrena Amézaga R
Gastroenterol Hepatol; 2011; 34(7):492-503. PubMed ID: 21550145
[TBL] [Abstract][Full Text] [Related]
25. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Park JG; Park SY
Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
[TBL] [Abstract][Full Text] [Related]
26. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
[TBL] [Abstract][Full Text] [Related]
27. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
[TBL] [Abstract][Full Text] [Related]
28. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.
Wu Y; Jie Y; Li X; Huang M; Li X; Shi H; Chen S; Zhang M; Ao Y; Yang F; Gao Z; Lin G; Chong Y
Clin Res Hepatol Gastroenterol; 2016 Apr; 40(2):213-20. PubMed ID: 26598028
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
Shan C; Yin GQ; Wu P
J Med Case Rep; 2014 Aug; 8():281. PubMed ID: 25146249
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
[TBL] [Abstract][Full Text] [Related]
32. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
Zuo SR; Zuo XC; Wang CJ; Ma YT; Zhang HY; Li ZJ; Song LY; Deng ZZ; Liu SK
J Clin Pharmacol; 2015 Mar; 55(3):288-97. PubMed ID: 25293471
[TBL] [Abstract][Full Text] [Related]
33. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
Guo X; Wu J; Wei F; Ouyang Y; Li Q; Liu K; Wang Y; Zhang Y; Chen D
Int J Antimicrob Agents; 2018 Aug; 52(2):201-209. PubMed ID: 29654894
[TBL] [Abstract][Full Text] [Related]
34. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
36. Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
De Francesco MA; Gargiulo F; Spinetti A; Zaltron S; Giagulli C; Caccuri F; Castelli F; Caruso A
New Microbiol; 2015 Jan; 38(1):29-37. PubMed ID: 25742145
[TBL] [Abstract][Full Text] [Related]
37. [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Buti M
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():32-8. PubMed ID: 19100229
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
Yu S; Zhou Q; Zhao XM; Yuan M; Wang CT; Cheng XG; Zhang ZH; Li X
Saudi J Gastroenterol; 2014; 20(6):350-5. PubMed ID: 25434315
[TBL] [Abstract][Full Text] [Related]
40. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Leung N
Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
